Bioprocessing technologies and systems

Search documents
Repligen to Report Second Quarter 2025 Financial Results
Globenewswire· 2025-07-17 11:30
Core Viewpoint - Repligen Corporation will report its second quarter 2025 financial results on July 29, 2025, and will host a conference call to discuss these results and business updates [1] Group 1: Financial Reporting - The financial results for the three- and six-month periods ended June 30, 2025, will be discussed during the conference call [1] - A press release will be issued before the market opens on the same day [1] Group 2: Conference Call Details - The conference call can be accessed by dialing toll-free (800) 715-9871 for domestic callers and (646) 307-1963 for international callers, with no passcode required [2] - A webcast will also be available via the Investor Relations section of the Company's website, and both the call and webcast will be archived for later access [2] Group 3: Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies for the manufacturing of biological drugs [3] - The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, with a focus on areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - The corporate headquarters is located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional key locations in Europe [3]
Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report
GlobeNewswire News Room· 2025-05-27 11:30
Core Insights - Repligen Corporation has published its 2024 Corporate Sustainability Report themed "Perspectives on Progress," highlighting advancements in sustainability across six key impact areas: Products & Packaging, Operations, Talent, Supply Chain, Communities, and Partnerships & Pathways [1][2] - The report includes disclosures aligned with the United Nations Sustainable Development Goals (UN SDGs) and key reporting frameworks such as the Global Reporting Initiative (GRI) Standards and Sustainability Accounting Standards Board (SASB) [1] Sustainability Highlights - The company transitioned to 100% renewable electricity across all 19 manufacturing sites, representing 100% of total global consumption [6] - Waste generation was reduced by 25%, and total waste intensity decreased by 32% on a normalized-to-revenue basis from 2023 to 2024 [6] - The global Scope 3 emissions inventory was expanded to cover all material emissions categories, increasing from 9 to 11 out of 15 compared to 2023 [6] - Repligen completed the UNGC Network USA Business and Human Rights Accelerator program, integrating the learnings into its corporate sustainability strategy [6] - A new customer-focused Repligen Training and Innovation Center (RTIC) was opened in Waltham, MA [6]
Repligen Corporation to Present at William Blair Growth Conference
Globenewswire· 2025-05-22 11:30
Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies and systems that enhance the manufacturing efficiency of biological drugs [3] - The company primarily serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide [3] - Key focus areas include Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] Upcoming Event - Repligen will participate in the William Blair 45th Annual Growth Stock Conference from June 3 to June 5 in Chicago [1] - Olivier Loeillot, President and CEO, is scheduled to present a company overview on June 3 at 1:20 p.m. CT [1] - A live webcast of the presentation will be available on Repligen's Investor Relations website and will be accessible for replay for a limited time after the event [2]
Repligen Corporation to Present at Upcoming May Investor Conferences
Globenewswire· 2025-05-07 11:30
Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies and systems for manufacturing biological drugs [3] - The company operates primarily in areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - Repligen's headquarters is located in Waltham, Massachusetts, with manufacturing sites in the U.S. and additional locations in Estonia, France, Germany, Ireland, the Netherlands, and Sweden [3] Upcoming Events - Repligen will participate in the RBC Capital Markets' 2025 Global Healthcare Conference in New York on May 20-21, where CFO Jason K. Garland will engage in an analyst-led discussion and one-on-one meetings with investors [4] - The company will also attend Craig-Hallum's 22nd Annual Institutional Investor Conference in Minneapolis on May 28, with CFO Jason K. Garland participating in one-on-one meetings [4] Investor Relations - A live webcast of the RBC conference presentation will be available on Repligen's Investor Relations website, with a replay accessible for a limited time after the event [2]
Repligen to Report First Quarter 2025 Financial Results
Globenewswire· 2025-04-15 11:30
Core Points - Repligen Corporation will report its first quarter 2025 financial results on April 29, 2025, with a conference call scheduled for 8:30 a.m. ET to discuss business updates and financial results for the period ending March 31, 2025 [1] Group 1: Financial Reporting - The company will issue a press release before the market opens on the reporting date [1] - A conference call will be accessible for domestic and international callers, with no passcode required for the live call [2] Group 2: Company Overview - Repligen Corporation is a global life sciences company focused on developing and commercializing innovative bioprocessing technologies for manufacturing biological drugs [3] - The company serves biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide, with a focus on Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins [3] - The corporate headquarters is located in Waltham, Massachusetts, with manufacturing sites primarily in the U.S. and additional key sites in Europe [3]